Literature DB >> 1765939

The neutrophil: mechanisms of controlling periodontal bacteria.

K T Miyasaki1.   

Abstract

The control of potentially periodontopathic microorganisms by host neutrophils is crucial to periodontal health. Neutrophils may use oxidative or nonoxidative mechanisms and either kill bacteria, influence bacterial growth, or modify bacterial colonization in the periodontium. Delivery of antimicrobial substances by neutrophils involves respiratory burst activity, phagocytosis, secretion, or cytolysis/apoptosis. Neutrophils contain a number of antimicrobial components including calprotectin complex, lysozyme, defensins, cofactor-binding proteins, neutral serine proteases, bactericidal/permeability increasing protein, myeloperoxidase, and a NADPH oxidase system. Many of these components are multifunctional and exhibit several mechanisms of antimicrobial activity. When comparisons are made among periodontal bacteria, differences in sensitivity to different components are observed. A hypothesis of specific defense is presented: That specific periodontal diseases can result from the failure of specific aspects of the host immune system (the neutrophil, in particular) in its interaction with specific periodontal pathogens. Failure may be due to phenotypic variation (pleomorphism) within the host or bacterial evasive strategies.

Entities:  

Mesh:

Year:  1991        PMID: 1765939     DOI: 10.1902/jop.1991.62.12.761

Source DB:  PubMed          Journal:  J Periodontol        ISSN: 0022-3492            Impact factor:   6.993


  27 in total

1.  Alkaline conditions accelerate polymorphonuclear leukocyte apoptosis in vitro.

Authors:  B Leblebicioglu; J Walters
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

Review 2.  Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease.

Authors:  J R Korzenik; B K Dieckgraefe
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

3.  Effect of ciprofloxacin on killing of Actinobacillus actinomycetemcomitans by polymorphonuclear leukocytes.

Authors:  David A Cacchillo; John D Walters
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  Modulation of human neutrophil functions in vitro by Treponema denticola major outer sheath protein.

Authors:  Bina Puthengady Thomas; Chun Xiang Sun; Elena Bajenova; Richard P Ellen; Michael Glogauer
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

5.  Role of the capsular polysaccharide-like serotype-specific antigen in resistance of Actinobacillus actinomycetemcomitans to phagocytosis by human polymorphonuclear leukocytes.

Authors:  N Yamaguchi; M Kawasaki; Y Yamashita; K Nakashima; T Koga
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

Review 6.  Functional and clinical aspects of the myelomonocyte protein calprotectin.

Authors:  B Johne; M K Fagerhol; T Lyberg; H Prydz; P Brandtzaeg; C F Naess-Andresen; I Dale
Journal:  Mol Pathol       Date:  1997-06

7.  Peptoanaerobacter stomatis Primes Human Neutrophils and Induces Granule Exocytosis.

Authors:  E Jimenez Flores; S Tian; M Sizova; S S Epstein; R J Lamont; S M Uriarte
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

8.  The challenge of antioxidants to free radicals in periodontitis.

Authors:  Gowri Pendyala; Biju Thomas; Suchetha Kumari
Journal:  J Indian Soc Periodontol       Date:  2008-09

9.  Cleavage of human transferrin by Porphyromonas gingivalis gingipains promotes growth and formation of hydroxyl radicals.

Authors:  Véronique Goulet; Bradley Britigan; Koji Nakayama; Daniel Grenier
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Gingipains from Porphyromonas gingivalis increase the chemotactic and respiratory burst-priming properties of the 77-amino-acid interleukin-8 variant.

Authors:  Irundika H K Dias; Lindsay Marshall; Peter A Lambert; Iain L C Chapple; John B Matthews; Helen R Griffiths
Journal:  Infect Immun       Date:  2007-11-19       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.